Psychiatr. pro Praxi, 2009; 10(2): 67-71

Multiple sclerosis - psychoneuroimmunological disease of the central nervous system

MUDr. Eva Krasulová
Centrum pro demyelinizační onemocnění Neurologická klinika 1. LF UK a VFN Praha

Multiple sclerosis (MS) presents the most frequent demyelinating disease of the central nervous system (CNS) with autoimmune ethiology.

Immune system plays a key role in MS pathogenesis and any CNS area can be affected by its inflammatory activity with various

neurological and psychiatric symptoms. MS is a typical example of psychoneuroimmunological disease, which often requires multispecialty

cooperation in terms of both diagnostics and treatment (symptomatic therapy, psychiatric adverse events of MS treatment).

Precise diagnosis and early treatment is the only prevention of permanent disability in MS, the disease afflicting mainly young persons

(2nd–4th decade) with significant prevalence in the Czech Republic 100-150 per 100 000.

Keywords: multiple sclerosis, central nervous system, psychoneuroimmunology, treatment.

Published: May 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krasulová E. Multiple sclerosis - psychoneuroimmunological disease of the central nervous system. Psychiatr. praxi. 2009;10(2):67-71.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Havrdová E. Neuroimunologie. Praha: Maxdorf 2001: 180-263.
    2. Serafini B, Rosicarelli B, Magliozzi R, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004; 14(2): 164-174. Go to original source... Go to PubMed...
    3. Smith RS. The macrophage theory of depression. Med Hypotheses 1991; 35(4): 298-306. Go to original source... Go to PubMed...
    4. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50(1): 121-127. Go to original source... Go to PubMed...
    5. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the, ,McDonald Criteria". Ann Neurol 2005; 58(6): 840-846. Go to original source... Go to PubMed...
    6. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 29, 338(5): 278-285. Go to original source... Go to PubMed...
    7. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 19, 357(9268): 1576-1582. Go to original source... Go to PubMed...
    8. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000; 28, 343(13): 898-904. Go to original source... Go to PubMed...
    9. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 4, 370(9585): 389-397. Go to original source... Go to PubMed...
    10. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39(3): 285-294. Go to original source... Go to PubMed...
    11. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, doubleblind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45(7): 1268-1276. Go to original source... Go to PubMed...
    12. Paty DW, Li DK. Interferon beta-1b is effective in relapsingremitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993; 43(4): 662-667. Go to original source... Go to PubMed...
    13. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998; 7, 352(9139): 1498-1504.
    14. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998; 43(1): 79-87. Go to original source... Go to PubMed...
    15. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995; 45(7): 1277-1285. Go to PubMed...
    16. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 2, 354(9): 899-910. Go to original source... Go to PubMed...
    17. Sorensen PS, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 2002; 9(6): 557-563. Go to original source... Go to PubMed...
    18. Feinstein A. The clinical neuropsychiatry of multiple sclerosis. Second Edition, Cambridge University Press 2007. Go to original source...
    19. Karussis D, Biermann LD, Bohlega S, et al. A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting. Eur J Neurol 2006; 13(1): 61-71. Go to original source... Go to PubMed...
    20. The IFNB Multiple Sclerosis Study Group. Interferon betalb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43(4): 655-661. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.